|Other author/creator||Bain, Lisa J., author.|
|Other author/creator||Stroud, Clare, author.|
|Other author/creator||Institute of Medicine (U.S.). Forum on Neuroscience and Nervous System Disorders, sponsoring body.|
|Other author/creator||Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation, sponsoring body.|
||Introduction and overview -- The burden of cognitive dysfunction in depression -- State of the science: treatment development -- Challenges and potential solutions to enable development of successful treatments -- Regulatory issues -- Lessons learned from the schizophrenia field.
||Major depressive disorder (MDD) is recognized worldwide as a major cause of disability, morbidity, and mortality. According to the World Health Organization, unipolar depressive disorders affect more than 150 million people around the world and represent the leading cause of years lost due to disability among both men and women. In the United States alone, nearly 8 percent of persons over the age of 12 report current depression. MDD has long been defined primarily as a mood disorder. However, more recently people have begun to recognize effects on cognition as a major contributor to the disablement that accompanies depression and to consider this an underrecognized treatment target for depression. To explore how best to enable the discovery, development, and translation of treatments for cognitive dysfunction in depression, including a focus on the regulatory path forward, the Institute of Medicine's Forum on Neuroscience and Nervous Disorders convened key stakeholders at a workshop in February 2015. This report summarizes the presentations from expert speakers and discussions among workshop participants.
|General note||Title from PDF title page.|
|Bibliography note||Includes bibliographical references.|
|Funding information||This activity was supported by contracts between the National Academy of Sciences and the Alzheimer's Association; Brain Canada Foundation; the Department of Health and Human Services' Food and Drug Administration and National Institutes of Health (NIH, Contract No. HHSN26300026 [Under Master Base #DHHS-10001292]) through the National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and NIH Blueprint for Neuroscience Research; the Department of Veterans Affairs (VA240-14-C-0057); Eli Lilly and Company; Foundation for the National Institutes of Health; the Gatsby Charitable Foundation; GlaxoSmithKline, Inc.; Johnson & Johnson Pharmaceutical Research and Development, LLC; Lundbeck Research USA; Merck Research Laboratories; The Michael J. Fox Foundation for Parkinson's Research; the National Multiple Sclerosis Society; the National Science Foundation (BCS-1064270); One Mind for Research; Orion Bionetworks; Pfizer Inc.; Pharmaceutical Product Development, LLC; Sanofi; the Society for Neuroscience; Takeda Pharmaceutical Company Limited; and Wellcome Trust. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.|
|Source of description||Version viewed December 21, 2015.|
|Issued in other form||Print version: Enabling Discovery, Development, and Translation of Treatments for Cognitive Dysfunction in Depression (Workshop) (2015 : Washington, D.C.). Enabling discovery, development, and translation of treatments for cognitive dysfunction in depression. Washington, D.C. : National Academies Press,  9780309373937|